General management strategy for epidermal growth factor receptor inhibitor-associated papulopustular eruption

J Am Acad Dermatol. 2016 Nov;75(5):e191. doi: 10.1016/j.jaad.2016.07.036.

Authors

Benjamin Farahnik¹, Bernice Kwong², Jenny Murase³

Affiliations

¹ University of Vermont College of Medicine, Burlington, Vermont; University of California San Francisco, Department of Dermatology, San Francisco, California. Electronic address: benjamin.farahnik@med.uvm.edu.
² Department of Dermatology, Stanford University School of Medicine, Stanford, California.
³ University of California San Francisco, Department of Dermatology, San Francisco, California; Department of Dermatology, Palo Alto Foundation Medical Group, Mountain View, California.

PMID: 27745649
DOI: 10.1016/j.jaad.2016.07.036

No abstract available

Keywords: chemotherapy side effect; epidermal growth factor receptor inhibitor; management; papulopustular eruption; xerosis.

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Anti-Infective Agents, Local / therapeutic use
Antibiotic Prophylaxis
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Drug Eruptions / drug therapy*
Drug Eruptions / etiology
Drug Eruptions / prevention & control
Emollients / therapeutic use
ErbB Receptors / antagonists & inhibitors*
Erythema / chemically induced
Humans
Neoplasm Proteins / antagonists & inhibitors*
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / therapeutic use
Pruritus / chemically induced
Skin Diseases, Bacterial / etiology
Skin Diseases, Bacterial / prevention & control
Sunscreening Agents / therapeutic use

Substances

Adrenal Cortex Hormones
Anti-Infective Agents, Local
Antineoplastic Agents
Emollients
Neoplasm Proteins
Protein Kinase Inhibitors
Sunscreening Agents
ErbB Receptors